Compare · DXCM vs ICCM
DXCM vs ICCM
Side-by-side comparison of DexCom Inc. (DXCM) and IceCure Medical Ltd. (ICCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and ICCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 4306.8x ICCM ($7.8M).
- ICCM has been more active in the news (22 items in the past 4 weeks vs 9 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 2 for ICCM).
- Company
- DexCom Inc.
- IceCure Medical Ltd.
- Price
- $89.16-2.09%
- $2.25-0.22%
- Market cap
- $33.65B
- $7.8M
- 1M return
- +21.53%
- -
- 1Y return
- +17.08%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 9
- 22
- Recent ratings
- 25
- 2
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
IceCure Medical Ltd.
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest ICCM
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
- West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
- SEC Form EFFECT filed by IceCure Medical Ltd.
- SEC Form EFFECT filed by IceCure Medical Ltd.
- VP, Sales for North America Good Shad was granted 131,483 units of Ordinary Shares, increasing direct ownership by 2,521% to 136,698 units (SEC Form 4)
- SEC Form 3 filed by new insider Salton David
- VP, BD & Global Marketing Tel-Tzure Tlalit Bussi was granted 101,483 units of Ordinary Shares, increasing direct ownership by 2,016% to 106,518 units (SEC Form 4)
- VP, Human Resources Dotan Merav Nir was granted 73,890 units of Ordinary Shares, increasing direct ownership by 3,244% to 76,168 units (SEC Form 4)
- SEC Form 4 filed by Director Chan Vincent Chun Hung